The European Commission has approved a higher dose of Novo Nordisk’s Wegovy (semaglutide), offering a potentially more effective treatment option for adults struggling with obesity. This decision, finalized on February 16, 2026, provides physicians with greater flexibility in tailoring weight loss treatments to individual patient needs. The approval follows a positive scientific opinion from the European Medicines Agency (EMA) in December 2025, signaling a significant step forward in addressing the growing global obesity epidemic. Wegovy, already available in several strengths, will now include a 7.2mg once-weekly maintenance dose, administered as three 2.4mg injections in a single session.
Obesity is a complex chronic disease with serious health consequences, including increased risk of heart disease, type 2 diabetes, and certain cancers. Current treatment options often fall short of delivering substantial and sustained weight loss, highlighting the require for innovative therapies like Wegovy. The availability of a higher dose aims to address this gap, offering patients a chance to achieve more significant reductions in body weight and improve their overall health. Novo Nordisk is as well seeking approval for a 7.2mg single-dose pen, which could simplify administration and improve patient convenience, with a potential launch later this year pending regulatory clearance.
EMA Review and Clinical Trial Data Support Higher Dose
The European Commission’s approval is based on robust data from the STEP-UP study, a Phase 3 clinical trial involving 1,407 participants with obesity but without diabetes. Published results demonstrate that patients receiving the 7.2mg dose of Wegovy, in conjunction with lifestyle interventions, experienced an average weight loss of 21%. This contrasts sharply with the placebo group, which saw an average weight loss of approximately 2%. Notably, around one-third of participants on the higher dose achieved a weight loss of 25% or more, a clinically significant outcome. Reuters reported on the approval on February 17, 2026.
Beyond the overall weight loss, the STEP-UP study also examined body composition. The data revealed that approximately 84% of the weight lost while on the 7.2mg dose was attributable to fat mass, while muscle function was preserved. Here’s a crucial finding, as maintaining muscle mass is essential for overall health and metabolic function during weight loss. As with other medications in this class – glucagon-like peptide-1 (GLP-1) receptor agonists – Wegovy can cause gastrointestinal side effects, including nausea, diarrhea, and vomiting, typically mild to moderate in severity and transient in nature.
Wegovy’s Expanding Global Reach and Pipeline Developments
The approval in the European Union builds on Wegovy’s existing availability in other markets. The drug was already approved for use at the 7.2mg dose in the United Kingdom in January 2026, and Novo Nordisk is actively pursuing regulatory approvals in the United States and other countries. This global expansion reflects the increasing recognition of obesity as a serious public health issue and the demand for effective treatment options.
Novo Nordisk isn’t solely focused on expanding the use of Wegovy. The company is also making significant strides in its pipeline, with ongoing research and development of next-generation obesity treatments. Notably, the company is developing UBT251, a novel triple agonist targeting GLP-1, GIP, and glucagon receptors. A Phase 2 clinical trial for UBT251 commenced on February 2, 2026, and is designed to enroll approximately 333 participants. ClinicalTrials.gov provides detailed information about the study protocol and progress. UBT251 was licensed from The United Laboratories in March 2025, and earlier Phase 1b data from China indicated an average weight reduction of 15.1% after 12 weeks in the highest dosage group.
Financial Strategy: Aktienrückkaufprogram and Market Position
Alongside its research and development efforts, Novo Nordisk is also actively managing its financial position. The company initiated a substantial share repurchase program in February, allocating 15 billion Danish kroner (DKK) for the buyback of its own shares. As of February 13, 2026, approximately 1.75 million B-shares had been repurchased at an average price of 305.03 DKK, totaling 533.8 million DKK. This program is scheduled to continue until May 4, 2026. Despite the positive regulatory news, Novo Nordisk’s stock has experienced some volatility, currently trading nearly 19% lower on a 30-day view, suggesting investor focus on valuation, competition, and the practical implementation of its obesity treatment strategy.
What Does This Signify for Patients and Healthcare Professionals?
The approval of the higher-dose Wegovy provides healthcare professionals with a valuable new tool in the fight against obesity. The increased efficacy demonstrated in clinical trials offers the potential for more substantial weight loss and improved health outcomes for patients. However, it’s crucial to remember that Wegovy is not a standalone solution. It should be used in conjunction with a comprehensive weight management program that includes lifestyle modifications, such as a healthy diet and regular physical activity.
For patients, the availability of a more effective treatment option offers renewed hope in their weight loss journey. However, it’s essential to have realistic expectations and to work closely with a healthcare provider to determine if Wegovy is the right choice. Potential side effects should be discussed, and ongoing monitoring is necessary to ensure safety and efficacy. The eventual availability of the 7.2mg pen will likely improve convenience and adherence to treatment.
Key Takeaways
- Higher Efficacy: The 7.2mg dose of Wegovy demonstrated a 21% average weight loss in clinical trials, significantly higher than the placebo group.
- Preserved Muscle Mass: A substantial portion of weight loss (84%) was attributed to fat mass, with muscle function maintained.
- Expanding Access: The approval in the EU, following UK approval, expands access to a more potent obesity treatment option.
- Pipeline Innovation: Novo Nordisk is actively developing UBT251, a next-generation triple agonist with promising early results.
- Financial Strength: The company’s share repurchase program demonstrates financial stability and confidence in its future prospects.
The European Commission’s decision underscores the growing recognition of obesity as a serious chronic disease requiring comprehensive and innovative treatment approaches. Novo Nordisk’s Wegovy, with its newly approved higher dose, represents a significant advancement in this field, offering hope for millions of individuals struggling with weight management. The company’s continued investment in research and development, coupled with its strategic financial management, positions it as a leader in the evolving landscape of obesity care.
Looking ahead, the focus will be on the rollout of the 7.2mg Wegovy dose across Europe and the potential approval of the single-dose pen. Further clinical trials will continue to evaluate the efficacy and safety of UBT251, paving the way for potential future treatment options. The ongoing monitoring of market dynamics and investor sentiment will also be crucial for Novo Nordisk as it navigates the competitive landscape of the weight loss market.
What are your thoughts on the approval of the higher-dose Wegovy? Share your comments below, and please share this article with your network to raise awareness about the latest advancements in obesity treatment.